Lisinopril and kidney disease
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril and Kidney Disease: A Comprehensive Review
Introduction to Lisinopril and Kidney Disease
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used in the management of hypertension and various kidney diseases. Its role in slowing the progression of renal disease, particularly in diabetic and non-diabetic nephropathies, has been extensively studied. This article synthesizes findings from multiple research studies to provide a clear understanding of the effects of lisinopril on kidney disease.
Lisinopril in Diabetic Nephropathy
Impact on Type 1 Diabetes (IDDM)
Research has shown that lisinopril can significantly slow the progression of renal disease in patients with insulin-dependent diabetes mellitus (IDDM). In a study involving 530 normotensive IDDM patients, lisinopril was found to reduce the albumin excretion rate (AER) by 51.3% in patients with the II genotype, compared to placebo . This suggests that ACE inhibitors like lisinopril can be particularly beneficial in early stages of diabetic nephropathy, especially in patients with specific genetic profiles.
Impact on Type 2 Diabetes (NIDDM)
In hypertensive patients with non-insulin-dependent diabetes mellitus (NIDDM) and diabetic nephropathy, lisinopril has been shown to reduce the rate of decline in kidney function more effectively than conventional antihypertensive treatments. A study comparing lisinopril and atenolol found that while both drugs effectively controlled blood pressure, lisinopril significantly reduced urinary albumin excretion by 55%, compared to 15% with atenolol . This indicates a superior renoprotective effect of lisinopril in diabetic nephropathy.
Lisinopril in Non-Diabetic Nephropathies
Mild Proteinuric Non-Diabetic Nephropathies
Lisinopril has also demonstrated efficacy in slowing the progression of renal insufficiency in patients with mild proteinuric non-diabetic nephropathies. A study involving 131 patients with chronic renal insufficiency showed that lisinopril significantly slowed the decline in renal function compared to other antihypertensive agents . This supports the hypothesis that ACE inhibitors have specific renoprotective effects beyond blood pressure control.
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
In patients with ADPKD, monotherapy with lisinopril was found to be effective in controlling blood pressure and slowing disease progression. A study comparing lisinopril alone to a combination of lisinopril and telmisartan (an ARB) found no significant difference in the decline of estimated glomerular filtration rate (GFR) between the two groups . This suggests that lisinopril alone is sufficient for managing hypertension and slowing renal decline in ADPKD.
Combination Therapies Involving Lisinopril
ACE Inhibitors and ARBs
While combination therapy with ACE inhibitors and ARBs has been explored, it has shown mixed results. A study involving patients with type 2 diabetes and diabetic nephropathy found that combination therapy did not significantly improve renal outcomes compared to monotherapy with lisinopril and was associated with increased risks of hyperkalemia and acute kidney injury . Therefore, the safety and efficacy of such combination therapies remain uncertain.
Lisinopril and GLP-1R Agonists
Emerging evidence suggests that combining lisinopril with glucagon-like peptide-1 receptor (GLP-1R) agonists, such as semaglutide, may offer additional nephroprotective benefits. In a mouse model of diabetic kidney disease, the combination of semaglutide and lisinopril significantly improved renal outcomes, including reductions in albuminuria and glomerulosclerosis . This indicates potential for combination therapies in enhancing renal protection.
Conclusion
Lisinopril has proven to be a valuable agent in managing various forms of kidney disease, particularly in diabetic nephropathy and mild proteinuric non-diabetic nephropathies. Its renoprotective effects, beyond blood pressure control, make it a critical component in the treatment of these conditions. However, the benefits and risks of combination therapies involving lisinopril require further investigation to ensure safety and efficacy.
Sources and full results
Most relevant research papers on this topic
Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril.
Nifedipine improves kidney transplant function more effectively than lisinopril over a 2-year period in hypertensive renal transplant patients treated with cyclosporin.
MO069: Therapeutic Effects of Semaglutide as Mono and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease
Semaglutide, alone or combined with lisinopril, significantly improves blood pressure, albuminuria, and glomerulosclerosis in a mouse model of hypertension-accelerated diabetic kidney disease.
Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.
Lisinopril has a specific renoprotective effect in addition to blood pressure control in patients with mild proteinuria, slowing the progression of non-diabetic chronic renal diseases.
DOI